Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

July 2014

Specialty Pharmacy Updates 


Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications.

Name Indication Coverage Available From
Actemra subcutaneous injection
(tocilizumab) 
Actemra  is used to treat adults with moderate to severe active rheumatoid arthritis who have not had a good response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs); patients age 2 and older with active polyarticular juvenile idiopathic arthritis; and patients age 2 and older with active systemic juvenile idiopathic arthritis. Pharmacy Benefit  Accredo
Capecitabine
(generic Xeloda) 
Capecitabine is an oral chemotherapy agent used to treat adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer. Pharmacy Benefit  Accredo
Myalept (metreleptin)  Myalept is approved as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.  Pharmacy Benefit  Accredo
Orenitram  (trepostinil)  Orenitram is used to reduce symptoms of certain kinds of pulmonary arterial hypertension (WHO Group 1) and improve exercise capacity. Pharmacy Benefit  Accredo
Rixubis
[coagulation Factor IX (recombinant)] 
Rixubis is used to prevent and control bleeding episodes in adults with hemophilia B. Medical Benefit  Accredo, Caremark
Tretten [coagulation Factor VIII A-Subunit (recombinant)]  Tretten is used to prevent bleeds in people with congenital factor XIII A-subunit deficiency.  Medical Benefit  Accredo
Vimizim
(elosulfase alfa) 
Vimizim is an enzyme replacement therapy for people with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)  Medical Benefit  Accredo

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

You’re Invited: Childhood Obesity Conference in Sept.

CLINICIAN CORNER

Prior Authorization Required for Immunobiologic Medications

Prior Authorization Required for Hyaluronate Injections for Osteoarthritis

Update of Cardiovascular Disease Risk Tests Policy

P&T Committee Updates

Specialty Pharmacy Updates

Screening for Eating Disorders in the Primary Care Setting

OFFICE ASSISTANT

Update: Durable Medical Equipment Payment Policy

New Medical Policy for Pulse Oximeters

Changes to Dialysis Network

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,
Editor

Kristin Edmonston,
Production Coordinator